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The majority of squamous cell carcinomas of cervix are preceded by visible changes in the cervix, most often detected by cervical
s m e a r .A sc e r v i c a lc a n c e ri sp r e c e d e db yl o n gp r e c a n c e r o u ss t a g e s, identiﬁcation of the high-risk population through detection
of DNA ploidy may be of importance in eﬀective management of this disease. Here we attempted to correlate aneuploid DNA
patternsandtheirinﬂuenceonbiologicalbehaviorofﬂow-cytometryanalysisofDNAploidywhichwascarriedoutincytologically
diagnosed cases of mild (79), moderate (36), and severe (12) dysplasia, as well as “atypical squamous cells of unknown signiﬁcance
(ASCUS)” (57) along with controls (69), in order to understand its importance in malignant progression of disease. Cytologically
diagnosed dysplasias, which were employed for DNA ploidy studies, 39 mild, 28 moderate, and 11 severe dysplasia cases were
found to be aneuploid. Out of the 69 control subjects, 6 cases showed aneuploidy pattern and the rest 63 subjects were diploid. An
aneuploidy pattern was observed in 8 out of 57 cases of cytologically evaluated ASCUS. The results of the followup studies showed
that aberrant DNA content reliably predicts the occurrence of squamous cell carcinoma in cervical smear. Flow cytometric analysis
of DNA ploidy may provide a strategic diagnostic tool for early detection of carcinoma cervix. Therefore, it is a concept of an HPV
screening with reﬂex cytology in combination with DNA ﬂow cytometry to detect progressive lesions with the greatest possible
sensitivity and speciﬁcity.
Copyright © 2008 M. Singh et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Cervical cancer is the second most common malignancy in
women worldwide. It is estimated that, globally, 466,000
new cases of cervical cancer are diagnosed each year. As per
estimate 231,000 women in a year die of cervical cancer
and 80% of them are from the developing world [1].
Use of cytological screening technique, Papanicolaou (Pap)
test, has signiﬁcantly increased the detection of cervical
cancer [2]. Cancer of cervix emerges from a deﬁned series
of preneoplastic lesions with increasing cellular dysplasia,
referred to as cervical intraepithelial neoplasia (CIN) grade
I, II, and III. However, CIN lesions frequently regress,
and not all CIN III lesions, progress to invasive cancer
[3]. The group of CIN is very heterogeneous, particularly
in their clinical behavior. Persistent infection with high-
risk-type human papilloma viruses (HPVs) is the strongest
independent risk factor for cervical cancer [4]. CIN lesions
induced by HPV infection and genomes of these viruses were
detected in the vast majority of cervical cancer specimens
[5–7]. During the course of tumor initiation in an HPV-
infected cervical epithelial cell, an aneuploid DNA pattern
develops [8], which along with its descendants shows genetic
instability. Aneuploidy reﬂects a situation of uncontrolled
increase of DNA and loss of essential information [9]
and plays an important role in neoplastic transformation.
Increased aneuploid DNA value with the increase in grades
of cervical dysplasia has long been considered to be a
speciﬁc prognostic marker of malignancy [10]. However, at
present, no well-established technique, which, qualitatively,
predicts the clinical outcome of cervical dysplasia except Pap
smear screening, is available. Approximately 15–30% of all
women who developed low-grade squamous intraepithelial
lesion (LSIL) have a probability of developing moderate-
to-severe cervical intraepithelial neoplasia (CIN II and III)
identiﬁed on a subsequent cervical biopsy [11]. To prevent
cervical malignancy and its precursors, several adjuvant
diagnostic methods have been proposed to strengthen the
accuracy of cytological and histological diagnosis [12]. As
chromosomal aneuploidy has been used as an early key event2 Journal of Cancer Epidemiology
in tumorigenesis caused by genetic instability [13, 14], the
cytometricequivalenceofchromosomalaneuploidydetected
by DNA ﬂow-cytometry may serve as a marker of neoplasia
and provide valuable information for the diagnosis and
understandingofpathogenesisofcervicalcancer.Sinceaneu-
ploid pattern of DNA is a useful parameter for the prediction
of progression and persistence of “atypical squamous cells
of unknown signiﬁcance (ASCUS)”, low-grade squamous
intraepithelial lesion (LSIL/mild dysplasia/CIN I), and high-
grade squamous intraepithelial lesion (HSIL/moderate and
severe dysplasia/CIN II and III) in clinical practice, the
present study was designed to investigate whether alteration
in cellular/nuclear content predicts the occurrence of cancer
in cervical smears. We have thus estimated their DNA
content using ﬂow cytometry and compared it with the
cytological ﬁndings.
2. MATERIALS AND METHODS
2.1. Subjectsandsampling
The cases were derived from the ongoing outpatient cytology
screening at Department Obstetrics and Gynecology, King
George’sMedicalUniversity(Lucknow,India)forthepresent
study. Cytologically diagnosed 127 cases of dysplasia (79
mild, 36 moderate, and 12 severe), 57 cases of “atypical
squamous cells of unknown signiﬁcance (ASCUS)” and
69 controls, which enrolled during the period of 2004–
2006, were recruited from a prospective followup study to
understand the biological behavior and the natural history
of cervical precancerous lesions. None of the patients had
any previous history of CIN or had been treated for CIN. All
the control women had normal smears. Age of the subjects
ranged from 30 to 75 years.
An experienced gynecologist collected cervical samples
with blunt end of Ayer’s spatula. Two fresh spatulas were
u s e df o re a c hp r e p a r a t i o n .S m e a r sw e r eﬁ x e di na l c o h o la n d
stained according to Pap method. The blunt end of the
second spatula was transferred into a cryo tube immediately,
containing 3mL chilled PBS (7.2pH) and quick frozen
at −20◦C until further use for ﬂow-cytometric analysis.
P a t i e n t sw e r ef o l l o w e du pb yc y t o l o g i c a la sw e l la sD N Aﬂ o w
cytometric analysis.
2.2. Criteriaforcytologicalclassiﬁcation
Cytological screening was performed with conventional Pap
staining by trained cytologists. All slides were evaluated
according to the criteria of the Bethesda System [15].
Precancerous lesions of the uterine cervix were classiﬁed
as normal, ASCUS, LSIL (mild dysplasia/CIN grade I),
and HSIL (moderate dysplasia/CIN grade II, severe dyspla-
sia/CIN grade III and carcinoma in situ/CIS).
2.3. Criteriaformanagementofprecancerouslesions
To understand the biological behavior of cervical precancer-
ous lesions, the following criteria were followed.
(i) The cases initially diagnosed as LSIL (CIN I) and
HSIL(CINIIandIII)weremadetoundergoasecond
Pap smear test after 30 days.
(ii) Cytological conﬁrmed dysplasia cases were enrolled
for the followup with the consent of the patients.
(iii) Cases initially diagnosed as CIN III were subjected
to colposcopy directed biopsy on day 30 and were
directed to gynecologist for further management. A
cytological control examination was done after every
6 and 3 months for LSIL and HSIL subjects, respec-
tively, and were categorized as “returned to nor-
mal” (after the morphology normalized); progressed
(when presented with higher grade of dysplasia); and
with no change (when remained at the same grade of
dysplasia). The samples were also tested for the DNA
ploidy pattern.
(iv) ASCUS and all aneuploid cases from control group
were also followed for a period of one year.
2.4. Flow-cytometricDNAanalysis
To determine the cellular DNA content, the protocol of
Nicoletti et al. was followed [16]. In brief, cells were ﬁxed
withchilledethanolfor30minutesat4◦Ctemperature.After
adding propidium iodide (Sigma-Aldrich, Miss, USA), the
mixture was stored in dark for 1 hour at room temperature.
Lymphocytes were used for calibration. The maximum
permitted coeﬃcient of variation (CV) for calibration was
2%.Atotalof15,000cellswerecountedineachsample.DNA
histogram cell-cycle analysis was performed as described by
Rabinovitch [17], using ModFit LT for Mac V2.0 software
after excluding debris by using electronic gate. The events in
G0-G1, S, and G2-M phases of the cell cycle were counted.
Cases were regarded as acceptable for analysis if the CV of
the G0-G1 peak was 7.0. Lesions were classiﬁed as diploid,
tetraploid, or aneuploid. If two distinct G0-G1 peaks were
present with a DNA index of ≥1.15 (each containing ≥10%
of total cell population), the histogram was considered as
aneuploid (DNA content). By convention, the ﬁrst G0-G1
peak represented the diploid peak. Diploid and tetraploid
lesions were classiﬁed as nonaneuploid. Histogram patterns
were termed diploid if there was a single G0-G1 peak. A
histogram was classiﬁed as tetraploid only if a large peak
observed in G2-M (DNA index of 1.80–2.2), containing
≥20% of the total curve and was also associated with a
corresponding 8N peak.
2.5. Statisticalanalysis
EPI-INFO software was used for calculating the odd ratio
and χ2 (chi-square) values. A P-value of .05 or less was
considered statistically signiﬁcant (95% CI).
3. RESULTS
T h ec e r v i c a ls m e a r sw e r ed i v i d e di n t of o u rg r o u p s( s e e
Figure 1). The ﬁrst group qualiﬁed as normal and grouped
69 cases. The second group (57 cases) qualiﬁed as ASCUS.M. Singh et al. 3
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Figure 1: Showing representative cytological images of cervical smears stained according to Pap staining method (magniﬁcation: 40X): (a)
showing cells with normal morphology, (b) showing “atypical squamous cells of unknown signiﬁcance,” (c) showing cells of mild dysplasia
(LSIL/CIN I), (d) showing cells of moderate dysplasia (HSIL/CIN II), (e) showing cells of severe dysplasia (HSIL/CIN III). LSIL: low-grade
squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; CIN: cervical intraepithelial neoplasia.
Table 1: DNA ploidy pattern in control, ASCUS, and various grades of dysplasia cases.
DNA
ploidy (n)
Control
n (%)
ASCUS
n (%)
OR
(95%CI)
Mild
dysplasia
n (%)
OR
(95%CI)
Moderate
dysplasia
n (%)
OR
(95%CI)
Severe
dysplasia
n (%)
OR
(95%CI)
Aneuploidy 6 8 1.71NS 39 10.2∗ 28 36.75∗ 11 115.50∗
(92) (8.69%) (14.03%) (0.47–6.26) (49.36%) (3.71–29.7) (77.77%) (10.35–140.74) (91.66%) (11.75–5041.27)
Diploidy 63 49 1.00 40 1.00 8 1.00 1 1.00
(161) (91.03%) (85.96%) (50.36%) (22.22%) (8.33%)
Total (253) 69 57 79 36 12
Odd ratios (OR) were computed considering control cases as the base line category for the ASCUS and dysplasia groups.
Not signiﬁcant NSP ≥ .05, Statically signiﬁcant ∗P ≤ .001, n:N u m b e ro fc a s e s .
The third and fourth groups comprised of LSIL (79 cases)
and HSIL (48 cases; 36 cases in moderate dysplasia and 12
c a s e si ns e v e r ed y s p l a s i a ) .
A comparison of DNA content analysis with behavior
of LSIL or HSIL in patients having cytologically diagnosed
various grades of dysplasia along with the control and
A S C U Sg r o u p sw e r em a d e( Table 1). 127 cases of diﬀerent
gradesofdysplasiawereemployedforanalysisofDNAploidy
out of which 78 (62.99%) cases were aneuploid (39 mild, 28
moderate, and 11 cases of severe dysplasia) and remaining
49 (37.01%) cases (40 mild, 8 moderate, and 1 severe)
were nonaneuploid, that is, diploid (see Figure 2). In the
control and ASCUS groups, 6 (8.70%) and 8 (14.04%) cases
were found to be aneuploid, respectively (see Figure 2). The
association of aneuploidy with increasing grades of dysplasia
was found to be signiﬁcant (P ≤ .001; Table 1,s e eFigure 3).
All these cases with aneuploid DNA content and cyto-
logically diagnosed ASCUS and various grades of dysplasia
were followed up for 1 year at aforementioned intervals, in
order to study the behavior of aneuploid DNA in progres-
sion/regression/persistence of disease. Among 57 patients
with ASCUS, 49 (85.96%) diploid cases had smears that
returned to normal cytology and remaining 8 (14.04%)
aneuploid cases showed signs of progression/regression. One
patient presented with HSIL and three with LSIL after
one year period of followup. Remaining four aneuploid
cases of ASCUS group regressed to normal, as evident
from diploid DNA. Out of six aneuploid cases with normal
cytological diagnosis, 4 cases were followed, where only one
case represented progression of disease from normal to mild
dysplasia after a year.
A total of 79 patients who had diagnosis of LSIL, 75 cases
were followed up. Out of 39 aneuploid cases, 7 developed
moderate dysplasia (CIN II) and 30 cases presented with no
change in cytology (CIN I), after a period of six months
from the date of registration. All cases showed aneuploid4 Journal of Cancer Epidemiology
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Figure 2: Showing representative histograms of ﬂow-cytometric analysis of DNA contents of cervical smears in diﬀerent stages of dysplasia.
In each sample, 25,000 events were counted at FL2-A following staining with propidium iodide 50μg/mL for 30 minutes in dark at 4◦C. Y-
axis showing number of cells and X axis represents DNA ploidy. (a) Showing a diploid peak of DNA. (b) Showing a near diploid aneuploidy.
(c) Showing a hyperaneuploidy from severe dysplasia patient. DI shows DNA index.
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Figure 3: Histogram showing percent incidence of anuploidy
in control, atypical squamous cells of unknown signiﬁcance and
various grade of dysplasia.
DNA in their followup study. 35 cases who had LSIL with
nonaneuploid DNA returned to normal and one patient
presented with no change in cytology, that is, remained
at CIN I. The sample for this particular subject showed
aneuploid DNA content of cell in followup study while 35
normal cases were diploid (Table 2).
Out of 36 cases of moderate dysplasia, only 30 patients
were available for followup study and 6 patients underwent
hysterectomy. 20 patients out of 25 who were diagnosed
with moderate dysplasia (HSIL/CIN II) and with aneuploid
DNA remained CIN II (71.79%) with an aneuploid DNA
in their followup study after three months of registration.
In addition, 2 other patients were diagnosed later with CIS,
who were positive for aneuploid DNA in their followup. 1
patient with diploid DNA remained at CIN II in cytological
followup and other 4 diploid showed a regressive pattern.
Outof 11only 3aneuploid casesofseveredysplasia (CINIII)
were followed, rest underwent prescribed treatment. Of the 3
cases, which were aneuploid, 1 case progressed to CIS and
2 remained at CIN III. The association of aneuploidy with
progression of disease was found to be signiﬁcant (Table 2).
χ2 test value for LSIL (P ≤ .001) and HSIL (P ≤ .001) was
signiﬁcant.
4. DISCUSSION
Thereisevidencethatcervicalcarcinomaevolvesonthebasis
of persistence of aneuploidy [10]. Studies have shown that
aneuploid conditions indicate either invasive carcinoma or
prospective neoplastic development in cervical dysplasia [18,
19]andplay acausalrole in neoplastic development [20,21].
Genetic abnormalities, such as numerical chromoso-
mal aberrations (aneuploidy and tetraploidy), have been
reported in women diagnosed with precancerous and can-
cerous cervical lesions and are observed frequently in the
presence of HPV infections [10, 22, 23]. According toM. Singh et al. 5
Table 2: Progression/regression pattern of diploid and aneuploid cases of dysplasia during follow up.
Groups Total cases Ploidy Status Progression Regression Chisquare
(n)( n)( n)( n)v a l u e
Mild 75 Aneuploid (39) 37 2 63.5∗∗
dysplasia Diploid (36) 1 35
Moderate/severe 33 Aneuploid (28) 25 3 8.4∗
dysplasia Diploid (5) 1 4
∗P ≤ .01, ∗∗P ≤ .001.
n:N u m b e ro fc a s e s .
Melsheimeretal.[22],deregulatedviraloncogeneexpression
appears to result ﬁrst in chromosomal instability and
aneuploidization and is subsequently followed by inte-
gration of HPV genomes in the aﬀected cell clones. In
CIN and invasive cervical cancer, DNA ploidy assessment
by ﬂow cytometric technique has been established as a
prognostic factor that allows the estimation of the relative
progressive risk into more advanced lesions [8, 24–27].
Dysplastic epithelium represents potentially precancerous
conditions in which the risk of progression to cancer is
usually unknown. Bocking and Motherby [28]s u g g e s t e d
that the identiﬁcation of DNA aneuploidy in dysplastic
squamous epithelia could increase the predictive value
for malignant transformation to over 90%. Similarly, the
results of our study have also conﬁrmed the predictive
value of aneuploidy with 92% aneuploid cases in all
grades of dysplasia showing progressive pattern of disease
(Table 2).
Evidences indicate aberrant DNA content in cells as a
cause rather than as a consequence of malignant transfor-
mation [29, 30]. Duesberg et al. pointed out that aneuploid
cancers are generally considered to be more dangerous and
aggressive than the diploid [31]. Boecking et al. carried
out a prospective study to determine the progression to
malignancy of cervical smears with ASCUS [32]. Based
on “the high prognostic validity of DNA-aneuploidy”
researchers concluded that the “aneuploid lesions should
immediately be controlled histologically or be removed”. In
accordance with the above ﬁndings, the results of the present
study also demonstrate the progressive pattern of disease
among aneuploid cases from ASCUS group. Bollmann et
al. suggested that ASCUS cases, those with high-risk HPV
and with abnormally high DNA content, represent similar
biologic featuresas HSIL with elevated risk to develop cancer
[33]. Thus, DNA content may reﬂect genomic instability of
the cells very early in the malignant process, at a point where
morphological changes in malignancies or premalignancies
are not yet evident [34]. Conceivably, lesions that are deﬁned
as nondysplastic, and therefore considered to represent
minimalornoriskfordevelopingcancercervix,maycontain
readily detectable large-scale genomic alteration viz DNA
aneuploidy which could signal a malignant transformation
[34, 35]. The identiﬁcation of a molecular biomarker of
persistent HPV infection in women who had been diagnosed
as normal/ASCUS in Pap smear could be a valuable tool in
the proper management of this disease. We have also found
6 aneuploid cases from control group and among them, after
one-year duration, one case presented the progression of
disease.
Inthisstudy,wehaveshownthataneuploidDNAcontent
could be used as a biomarker of progressive cervical changes
towards malignancy. Progressive increase in aneuploidy
increases the severity of the lesions (49.36% for mild
dysplasia, 77.77% for moderate dysplasia versus 91.66% for
severe dysplasia). Our followup results clearly demonstrate
that more and more progressive pattern of disease was
noted in aneuploid cases and that DNA ploidy could be
used as a prognostic marker for cervical malignancies.
ComparisonofresultsobtainedwithPapscreeningandDNA
ploidy measurement provide a positive correlation between
aneuploid DNA and progression of disease (Table 2). Fur-
thermore, the percentage of aneuploid cases towards the
progression of disease was higher in followup data that
supported the prognostic value of aneuploidy as a marker
to identify the progressive behavior of lesion. Occurrence of
aneuploidywasexceptionalinpatientswhohadsampleswith
morphology that returned to normal, whereas, patients who
had cytological signs of disease progression were found with
a signiﬁcantly greater frequency (P<. 01, P<. 001; Table 2).
High-grade lesions (accordingto Bethesda classiﬁcation) can
be detected using cytodiagnosis method with generally good
accuracy, but the diagnosis occasionally relies on subjective
parameters. Moreover, inadequate sampling may result in a
mild morphologic change despite early progressive behavior
[36]. Thus, the measurement of DNA content by ﬂow
cytometry provides qualitative information and presence of
aberrant aneuploid cells in cytological samples, which could
serve as a useful parameter along with cytology with good
speciﬁcity and sensitivity [37, 38]. If patients at risk could
be identiﬁed earlier by analysis of parameter that reﬂects the
true biological properties of lesion, treatment regimes could
be given selectively to improve the current poor survival
rate of cancer cervix cases [39]. Flow cytometric analysis of
DNA ploidy may provide a strategic diagnostic tool for early
detection of carcinoma cervix [8, 25]. Therefore, we propose
the concept of an HPV screening with reﬂex cytology in
combination with DNA ﬂow cytometry to detect progressive
lesions with the greatest possible sensitivity and speciﬁcity.
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